Medicine and Dentistry
Non Small Cell Lung Cancer
99%
Lung Cancer
90%
Surgery
79%
Thorax Surgery
73%
Lung Transplantation
65%
Surgeon
58%
Neoplasm
57%
Esophageal Cancer
51%
Pneumonectomy
41%
Esophagectomy
41%
Metastatic Carcinoma
39%
Disease
36%
Malignant Neoplasm
33%
Cardiothoracics
32%
Methylation
26%
Chemoradiotherapy
23%
Oncology
22%
Lobectomy
22%
Recurrent Disease
21%
Overall Survival
21%
Nivolumab
20%
Lung Cancer Screening
20%
Esophagus
19%
Promoter Region
19%
Transplantation
19%
Adenocarcinoma
18%
Medical Student
16%
Pulmonary Hypertension
16%
Primary Tumor
15%
Diagnosis
14%
Scleroderma
14%
Surgical Anastomosis
14%
Esophageal Adenocarcinoma
14%
Allograft
14%
Postoperative Complication
14%
Cancer
14%
Neoadjuvant Therapy
13%
Immunotherapy
13%
Computer Assisted Tomography
13%
Thoracotomy
12%
Lymph Node
12%
Systemic Therapy
12%
Long Term Survival
11%
Cancer Treatment
11%
Cancer Surgery
11%
Gastroesophageal Junction
11%
Radiation Therapy
11%
Pancreas Adenocarcinoma
10%
Survival Rate
10%
Hazard Ratio
10%
Keyphrases
Non-small Cell Lung Cancer (NSCLC)
100%
NCCN Guidelines
62%
Esophageal Cancer
45%
Tumor
41%
Lung Transplantation
39%
Resection
25%
Combination Immunotherapy
25%
Lung Cancer
24%
Tumor Necrosis Factor-α
24%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
23%
Stage I Lung Cancer
19%
Interleukin-2
19%
Lung
18%
Lung Cancer Screening
18%
Metastasis
16%
Oncology
16%
Esophagectomy
15%
Pulmonary Resection
14%
Induction Therapy
14%
Cancer Treatment
14%
Surgical Training
13%
Overall Survival
13%
Thoracic Surgery
13%
Neoadjuvant
12%
Adenocarcinoma
12%
Neoadjuvant Chemoradiotherapy (nCRT)
11%
Promoter Methylation
11%
Long-term Survival
11%
Pathologic
11%
Multidisciplinary Approach
11%
Surgical Patients
11%
Low-dose interleukin-2
10%
Medical Students
10%
Esophageal Squamous Cell Carcinoma
10%
Nivolumab
10%
TP53 mutation
10%
Confidence Interval
10%
Methylation
10%
Postoperative Complications
9%
Scleroderma
9%
Cardiothoracic Surgery
9%
Neurofibromatosis Type 1 (NF-1)
9%
Mesothelioma
9%
Postoperative Pain Management
9%
Anti-CD3
9%
OKT3
9%
Esophageal Adenocarcinoma
9%
Early Cancer Detection
9%
Early Treatment
9%
Clinical Practice Guidelines
9%